Markets:

Overview

News

Currencies

International

Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

141.88 +3.17 (+2.29%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

PacBio (PACB) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

PacBio (PACB) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

5 Revealing Analyst Questions From Illumina’s Q1 Earnings Call

May 07, 2026

Illumina’s first quarter reflected consistent execution across its clinical and instrument businesses. Management highlighted strong demand in clinical seque...

Via StockStory

Topics Earnings

3 Profitable Stocks We’re Skeptical Of

May 06, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Illumina Q1 2026 Earnings Beat Overshadowed by Revenue Miss, ILMN Slides ↗

April 30, 2026

Via Chartmill

Topics Earnings

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

May 05, 2026

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results this Thursday after the bell. Here’s what to look for. 10x Genomics beat analys...

Via StockStory

PacBio (PACB) Q1 Earnings Report Preview: What To Look For

May 05, 2026

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting earnings this Thursday after market hours. Here’s what investors should kn...

Via StockStory

Uber, Exxon Mobil, Illumina, Diamondback Energy: CNBC's 'Final Trades' ↗

May 05, 2026

CNBC's Halftime Report Final Trades featured Bryn Talkington's final trade of Uber, whose shares fell 1.6% to close at $73.93 on Monday.

Via Benzinga

ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges

May 01, 2026

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 4.8% year on year to $1.09 bill...

Via StockStory

Illumina (ILMN) Q1 2026 Earnings Transcript ↗

April 30, 2026

Illumina (ILMN) Q1 2026 Earnings Transcript

Via The Motley Fool

Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

April 30, 2026

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 4.8% year on year to $1.09 billi...

Via StockStory

Illumina (ILMN) Q1 Earnings Report Preview: What To Look For

April 28, 2026

Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to look for. Illumina beat analysts’ revenue expectat...

Via StockStory

Topics Artificial Intelligence

UPS, Netflix, BlackRock And A Health Care Stock On CNBC's 'Final Trades' ↗

April 20, 2026

Stephen Weiss recommends Netflix as final trade, while Jason Snipe likes BlackRock. Amy Raskin suggests Illumina and Jenny Harrington chooses UPS.

Via Benzinga

Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A

April 15, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately...

Via MarketMinute

Topics Economy

3 Unpopular Stocks That Concern Us

April 13, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

3 Reasons to Avoid ILMN and 1 Stock to Buy Instead

April 09, 2026

In a sliding market, Illumina has defied the odds, trading up to $126.99 per share. Its 31.7% gain since October 2025 has outpaced the S&P 500’s 1.8% drop. T...

Via StockStory

Topics Stocks

1 Mid-Cap Stock for Long-Term Investors and 2 We Brush Off

March 31, 2026

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Via StockStory

Nasdaq Overhauls Index Rules to Capture Mega-Cap IPOs: The Era of 'Fast Entry' and Phantom Market Caps Begins

March 30, 2026

On March 30, 2026, Nasdaq (Nasdaq: NDAQ) announced the finalization of the most significant methodology overhaul to its flagship Nasdaq-100 Index in over a decade. Set to take effect on May 1, 2026,...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Economy Government Stocks

A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop ↗

March 23, 2026

Sotera Health delivers sterilization and lab testing services to global medical and pharmaceutical supply chains.

Via The Motley Fool

Abbott Laboratories Finalizes $21 Billion Acquisition of Exact Sciences, Redefining the Future of Cancer Diagnostics

March 23, 2026

CHICAGO — In a move that fundamentally reshapes the global diagnostics landscape, Abbott Laboratories (NYSE: ABT) officially completed its $21 billion acquisition of Exact Sciences (NASDAQ: EXAS)...

Via MarketMinute

Topics Supply Chain

Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders

March 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and it...

Via StockStory

Topics Artificial Intelligence

ADS and Gamma Scientific Release Joint White Paper on Practical Path to NHTSA ADB Compliance

March 17, 2026

Via PRLog

Illumina Stock Sees RS Rating Jump To 82 ↗

March 16, 2026

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Illumina stock cleared that benchmark Monday, jumping to 82.

Via Investor's Business Daily

3 Profitable Stocks with Open Questions

March 09, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Life Sciences Tools & Services Stocks Q4 In Review: 10x Genomics (NASDAQ:TXG) Vs Peers

March 05, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including 10x Genomics (NASDAQ:TXG) and its ...

Via StockStory

Topics Artificial Intelligence

Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB)

March 03, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its ...

Via StockStory

Topics Artificial Intelligence

The "Flight to Quality": Thermo Fisher’s Q4 Beat and Dividend Hike Cement Defensive Leadership for 2026

February 27, 2026

WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the...

Via MarketMinute

Topics Earnings Economy World Trade

What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally ↗

February 26, 2026

MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend.

Via The Motley Fool

Topics Energy

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

February 12, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only...

Via StockStory

Topics Stocks

5 Insightful Analyst Questions From Illumina’s Q4 Earnings Call

February 12, 2026

Illumina’s fourth quarter was marked by strong performance in its clinical consumables business, with management citing 20% year-over-year growth outside China as a key driver. CEO Jacob Thaysen...

Via StockStory

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.